Company Encyclopedia
View More
name
Yinhua CSI Innovative Drugs Industry ETF
159992.SZ
News
View More

HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

HSBC analyst Linda Shu has reaffirmed a Buy rating for Hangzhou Tigermed Consulting Co., Ltd. Class H, setting a price target of HK$54.00. The stock closed at HK$44.04. Shu, a 3-star analyst, has an average return of 8.0% and a 64.71% success rate. The overall analyst consensus for the company is a Strong Buy, with an average price target of €5.92, indicating a potential downside of -86.56%. CLSA also maintains a Buy rating with a target of HK$52.10.

Tip Ranks·
HK
03347
-3.10%
SZ
300347
-0.63%
Tip Ranks·
HK
03347
-3.10%
SZ
300347
-0.63%

Fosun Pharma Shareholders to Vote on Election of Mr. Liu Yi as Executive Director at Upcoming EGM

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. will hold its 2025 second extraordinary general meeting on December 2, 2025, where shareholders will vote on the election of Mr. Liu Yi as an executive director. The board recommends voting in favor of this proposal.

Reuters·
HK
02196
-1.58%
SH
600196
-0.91%
Reuters·
HK
02196
-1.58%
SH
600196
-0.91%
Posts
View More